• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA Gives OK for Viracta’s Phase Ib/II Trial of Oral Combo in Epstein-Barr Virus Tumors

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 21, 2021 at 09:12: PM
via The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase Ib/II trial of Viracta Therapeutics’ all-oral combination regimen in advanced Epstein-Barr Virus-Positive (EBV+) solid tumors. The study will also investigate the oral combination with PD-1 inhibitor pembrolizumab in EBV+ metastatic nasopharyngeal carcinoma (RM-NPC).

article source
 




Top Bottom
Back
Quote